Analysed CARDIFF ONCOLOGY INC (CRDF:NASDAQ) News Sources
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
09-04-2026
yahoo.com
Cardiff Oncology Showcases Onvansertib: 72% ORR Signal in Phase II RAS-Mutant mCRC Webinar
25-03-2026
marketbeat.com
Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
20-03-2026
yahoo.com
Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
19-03-2026
yahoo.com
Cardiff Oncology Spotlights Onvansertib Data at Oppenheimer: 72% ORR in RAS-Mutant mCRC
26-02-2026
marketbeat.com
What is the current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The current price of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is $1.58.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) absolute price change since previous trading day?
The absolute price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is $-0.09.
CARDIFF ONCOLOGY INC (CRDF:NASDAQ) percentage price change since previous trading day?
The percentage price change of CARDIFF ONCOLOGY INC (CRDF:NASDAQ) since the previous trading day is -5.3892%.
What is the most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent average sentiment score for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is 65 out of 100.
What is the most recent average sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ)?
The most recent sentiment for CARDIFF ONCOLOGY INC (CRDF:NASDAQ) is .
SEC-8K** Filing Available For CARDIFF ONCOLOGY INC (CRDF:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.